Cargando…

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects

A randomized, double‐blind clinical trial was conducted to investigate long‐term abuse effects of testosterone cypionate (TC). Thirty‐one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Youwei, Perry, Paul J., Ellerby, Michael, Murry, Daryl J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915615/
https://www.ncbi.nlm.nih.gov/pubmed/29436172
http://dx.doi.org/10.1002/psp4.12287
_version_ 1783316901693227008
author Bi, Youwei
Perry, Paul J.
Ellerby, Michael
Murry, Daryl J.
author_facet Bi, Youwei
Perry, Paul J.
Ellerby, Michael
Murry, Daryl J.
author_sort Bi, Youwei
collection PubMed
description A randomized, double‐blind clinical trial was conducted to investigate long‐term abuse effects of testosterone cypionate (TC). Thirty‐one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link exposure to change in luteinizing hormone and spermatogenesis following long‐term TC administration. A linear one‐compartment model best described the concentration‐time profile of total testosterone. The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe and of greater duration in the 250 mg and the 500 mg dose groups.
format Online
Article
Text
id pubmed-5915615
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59156152018-04-25 Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects Bi, Youwei Perry, Paul J. Ellerby, Michael Murry, Daryl J. CPT Pharmacometrics Syst Pharmacol Article A randomized, double‐blind clinical trial was conducted to investigate long‐term abuse effects of testosterone cypionate (TC). Thirty‐one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link exposure to change in luteinizing hormone and spermatogenesis following long‐term TC administration. A linear one‐compartment model best described the concentration‐time profile of total testosterone. The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe and of greater duration in the 250 mg and the 500 mg dose groups. John Wiley and Sons Inc. 2018-03-01 2018-04 /pmc/articles/PMC5915615/ /pubmed/29436172 http://dx.doi.org/10.1002/psp4.12287 Text en © 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Article
Bi, Youwei
Perry, Paul J.
Ellerby, Michael
Murry, Daryl J.
Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
title Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
title_full Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
title_fullStr Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
title_full_unstemmed Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
title_short Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
title_sort population pharmacokinetic/pharmacodynamic modeling of depot testosterone cypionate in healthy male subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915615/
https://www.ncbi.nlm.nih.gov/pubmed/29436172
http://dx.doi.org/10.1002/psp4.12287
work_keys_str_mv AT biyouwei populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects
AT perrypaulj populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects
AT ellerbymichael populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects
AT murrydarylj populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects